Head to Head Comparison: iTeos Therapeutics (NASDAQ:ITOS) & Invivyd (NASDAQ:IVVD)

Invivyd (NASDAQ:IVVD) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, valuation, institutional ownership, risk, earnings, dividends and profitability.

Earnings & Valuation

This table compares Invivyd and iTeos Therapeutics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Invivyd	$11.56 million	4.68	-$198.64 million	($1.96)	-0.23
iTeos Therapeutics	$35.00 million	8.10	-$112.64 million	($3.15)	-2.46

iTeos Therapeutics has higher revenue and earnings than Invivyd. iTeos Therapeutics is trading at a lower price-to-earnings ratio than Invivyd, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

70.4% of Invivyd shares are held by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are held by institutional investors. 17.9% of Invivyd shares are held by company insiders. Comparatively, 12.5% of iTeos Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Invivyd has a beta of 0.64, indicating that its stock price is 36% less volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.39, indicating that its stock price is 39% more volatile than the S&P 500.

Profitability

This table compares Invivyd and iTeos Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Invivyd	N/A	-155.33%	-114.88%
iTeos Therapeutics	N/A	-20.11%	-17.50%

Analyst Ratings

This is a summary of current ratings and recommmendations for Invivyd and iTeos Therapeutics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Invivyd	0	0	4	1	3.20
iTeos Therapeutics	0	0	4	0	3.00

Invivyd presently has a consensus price target of $7.89, indicating a potential upside of 1,645.02%. iTeos Therapeutics has a consensus price target of $22.25, indicating a potential upside of 186.73%. Given Invivyd’s stronger consensus rating and higher possible upside, equities research analysts plainly believe Invivyd is more favorable than iTeos Therapeutics.

Summary

iTeos Therapeutics beats Invivyd on 7 of the 13 factors compared between the two stocks.

About Invivyd

Invivyd, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19. The company also has discovery stage candidates for the prevention of seasonal influenza and COVID-19. It has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was formerly known as Adagio Therapeutics, Inc. and changed its name to Invivyd, Inc. in September 2022. Invivyd, Inc. was incorporated in 2020 and is headquartered in Waltham, Massachusetts.

About iTeos Therapeutics

Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients with cancer. The company's lead antibody product candidate, belrestotug, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells, natural killer cells, and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Its product pipeline also includes inupadenant, a next-generation A2AR antagonists that is in Phase 1/2a clinical trials to overcome the specific adenosine-mediated immunosuppression found in tumor microenvironment; and EOS-984, a small molecule targeting equilibrative nucleoside transporter 1 (ENT1) to inhibit the immunosuppressive activity of adenosine and restore immune cell proliferation is in Phase 1 clinical trials. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.